Fragment approaches have established themselves over the last few decades as a powerful approach for interrogating drug targets and discovering new biologically active compounds in a relatively short time. By the end of 2021 there were 6 fragment-derived drugs in the clinic: in order of approval: Zelboraf (vemurafenib), Venetoclax (ABT-199), Erdafitinib, Pexidartinib (PLX2297), Sotorasib (AMG-510) and Asciminib (ABL001). Two of these moved through the drug discovery pipeline relatively quickly: Zelboraf progressed from an unselective fragment to a highly selective cancer drug in the span of 6 years; and Sotorasib took 8 years from a publication, demonstrating the druggability of its target K-RAS G12C to an FDA approved drug.